EUVIMEDEUVIMED entdecken
Open Access

Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge

Gang Wang, Abhishek K Verma, Xiaoqing Guan, Fan Bu, Abby E Odle, Fang Li iD, Bin Liu iD, Stanley Perlman iD, Lanying Du iD

Journal of Virology · 2024

DOI: 10.1128/jvi.00376-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Gang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, SARS-CoV-2, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Three highly pathogenic coronaviruses (CoVs), SARS-CoV-2, SARS-CoV, and MERS-CoV, belonging to the genus beta-CoV, have caused outbreaks or pandemics. SARS-CoV-2 has evolved into many variants with increased resistance to the current vaccines. Spike (S) protein and its receptor-binding domain (RBD) fragment of these CoVs are important vaccine targets; however, the RBD of the SARS-CoV-2 Omicron variant is highly mutated, rending neutralizing antibodies elicited by ancestral-based vaccines targeting this region ineffective, emphasizing the need for effective vaccines with broad-spectrum efficacy against SARS-CoV-2 variants and other CoVs with pandemic potential. This study describes a pan-beta-CoV subunit vaccine, Om-S-MERS-RBD, by fusing the conserved and highly potent RBD of MERS-CoV into an RBD-truncated SARS-CoV-2 Omicron S protein, and evaluates its neutralizing immunogenicity and protective efficacy in mouse models. Om-S-MERS-RBD formed a conformational structure, maintained effective functionality and antigenicity, and bind efficiently to MERS-CoV receptor, human dipeptidyl peptidase 4, and MERS-CoV RBD or SARS-CoV-2 S-specific antibodies. Immunization of mice with Om-S-MERS-RBD and adjuvants (Alum plus monophosphoryl lipid A) induced broadly neutralizing antibodies against pseudotyped MERS-CoV, SARS-CoV, and SARS-CoV-2 original strain, as well as T-cell responses specific to RBD-truncated Omicron S protein. Moreover, the neutralizing activity against SARS-CoV-2 Omicron subvariants was effectively improved after priming with an Omicron-S-RBD protein. Adjuvanted Om-S-MERS-RBD protein protected mice against challenge with SARS-CoV-2 Omicron variant, MERS-CoV, and SARS-CoV, significantly reducing viral titers in the lungs. Overall, these findings indicated that Om-S-MERS-RBD protein could develop as an effective universal subunit vaccine to prevent infections with MERS-CoV, SARS-CoV, SARS-CoV-2, and its variants. IMPORTANCE Coronaviruses (CoVs), SARS-CoV-2, SARS-CoV, and MERS-CoV, the respective causative agents of coronavirus disease 2019, SARS, and MERS, continually threaten human health. The spike (S) protein and its receptor-binding domain (RBD) fragment of these CoVs are critical vaccine targets. Nevertheless, the highly mutated RBD of SARS-CoV-2 variants, especially Omicron, significantly reduces the efficacy of current vaccines against SARS-CoV-2 variants. Here a protein-based pan-beta-CoV subunit vaccine is designed by fusing the potent and conserved RBD of MERS-CoV into an RBD-truncated Omicron S protein. The resulting vaccine maintained effective functionality and antigenicity, induced broadly neutralizing antibodies against all of these highly pathogenic human CoVs, and elicited Omicron S-specific cellular immune responses, protecting immunized mice from SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV infections. Taken together, this study rationally designed a pan-beta-CoV subunit vaccine with broad-spectrum efficacy, which has the potential for development as an effective universal vaccine against SARS-CoV-2 variants and other CoVs with pandemic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Middle East Respiratory Syndrome CoronavirusSARS-CoV-2Antibodies, NeutralizingSpike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, ViralCOVID-19AnimalsMiceHumansCOVID-19 VaccinesMice, Inbred BALB CViral VaccinesSevere acute respiratory syndrome-related coronavirusFemale

Stichwörter der Autor:innen

SARS-CoV-2broadly neutralizing activitycoronaviruscross-protective efficacyreceptor-binding domainspike

Substanzen

Antibodies, NeutralizingSpike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, ViralCOVID-19 VaccinesViral Vaccinesspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.
  • Department of Microbiology and Immunology, University of Iowa, Iowa City, lowa, USA.
  • Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Center for Coronavirus Research, University of Minnesota, Minneapolis, Minnesota, USA.
  • Hormel Institute, University of Minnesota, Austin, Minnesota, USA.
  • Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.

ORCID-Profile: Fang Li, Bin Liu, Stanley Perlman, Lanying Du

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Wang, G., Verma, A. K., Guan, X., Bu, F., Odle, A. E., Li, F., Liu, B., Perlman, S., & Du, L. (2024). Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. Journal of Virology. https://doi.org/10.1128/jvi.00376-24

Vancouver

Wang G, Verma AK, Guan X, Bu F, Odle AE, Li F, et al. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. Journal of Virology. 2024. doi:10.1128/jvi.00376-24

BibTeX
@article{Wang2024,
  author = {Wang, Gang and Verma, Abhishek K and Guan, Xiaoqing and Bu, Fan and Odle, Abby E and Li, Fang and Liu, Bin and Perlman, Stanley and Du, Lanying},
  title = {Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.00376-24}
}
Kostenlos starten →